Uniqueness of Albumin as a Carrier in Nanodrug Delivery

ABSTRACT In contemporary medicine, albumin nanoparticles have become a powerful and adaptable nanodrug carrier. The ability of human serum albumin to deliver hydrophobic drugs through passive and active targeting mechanisms demonstrates its versatility in treating a variety of disorders. In addition to discussing ongoing clinical trials using albumin-based formulations, this study emphasizes the benefits of albumin-bound Paclitaxel (Abraxane) over solvent-based formulations (Taxol). Future advancements in albumin-based therapeutics are made possible by the emphasis placed on the importance of albumin in improving drug performance and its potential as a drug delivery mechanism. Albumin nanoparticles show promise in the treatment of a variety of illnesses. This study emphasizes their use in the delivery of hydrophobic drugs, their benefits over formulations based on solvents, and their ongoing clinical trials. The medicinal potential of albuminNeutrophils, leveraging their inflammation-targeting capabilities, have emerged as innovative drug delivery carriers. Integrating neutrophils with nanotechnology enhances treatment efficacy and reduces side effects. This review explores neutrophil-based nano-drug delivery systems, including membrane-coated nanoparticles, cell-loaded nanoparticles, and chimeric antigen receptor (CAR)-neutrophils. These therapies demonstrate superior biocompatibility, targeting, and therapeutic robustness, showing promise in various disease treatments.Neutrophils, combined with nanotechnology, offer innovative drug delivery. This review covers design principles, mechanisms, and applications of neutrophil-based nano-drug delivery systems, highlighting enhanced biocompatibility, targeting, and therapeutic efficacy.